How Cancer Care Has Become More Personalised?

When you hear “personalised cancer care,” you’re not just hearing a buzzword; you’re hearing a shift in how doctors think about your tumour, your life, and your goals. Your treatment plan can now reflect your tumour’s unique genetic fingerprint, your cultural background, and even how you feel day to day. But the real change isn’t only in the lab tests or new drugs it’s in how every decision about your care is starting to look very different…

What Personalised Cancer Care Really Means

Personalised cancer care refers to tailoring diagnosis, treatment, and support to the specific characteristics of a person’s disease and circumstances. It begins with understanding the biology of the tumour, often through molecular and genetic tests that identify features such as mutations, protein expression, or other biomarkers. These findings can guide the selection of treatments, including targeted therapies and immunotherapies, when there's evidence that they're likely to be effective.

Personalisation also involves ongoing adjustment rather than a fixed plan. Clinicians monitor symptoms, treatment responses, and side effects using clinical assessments and patient‑reported outcomes. This information can lead to changes in medication doses, supportive care measures, or even a shift in treatment strategy over time.

Decision‑making typically involves a multidisciplinary team, such as oncologists, surgeons, radiologists, pathologists, and nurses, who review clinical data and evidence from research to recommend options. While advanced diagnostics and data play a significant role, individual values, preferences, and practical considerations are also taken into account through structured discussions between patients and healthcare professionals.

How Tumour Genetics Guide Personalised Treatment

When doctors analyse the genetic makeup of a tumour, they look for specific mutations and molecular changes that can influence which treatments are most appropriate. Using techniques such as next-generation sequencing, they can identify alterations like EGFR mutations in some lung cancers or BRAF mutations in certain colorectal cancers and gain insight into how the cancer is likely to respond to different therapies.

The resulting genetic profile helps guide treatment decisions, including the use of targeted drugs that act on mutated proteins and immunotherapies that focus on particular tumour markers. In some cases, liquid biopsies are used to detect circulating tumour DNA in the blood, allowing clinicians to monitor genetic changes over time.

Multidisciplinary molecular tumour boards may review these findings and integrate them with other clinical information to adjust treatment plans as the cancer evolves.

In private practice this level of profiling is increasingly treated as standard rather than as an optional extra. London clinical oncologist Dr James Wilson, who specialises in lung cancer, melanoma and metastatic disease, uses molecular testing and liquid biopsy monitoring to shape and then adjust treatment as results come in; his practice site at drjameswilson.co.uk explains how those findings feed into an individual plan.

Targeted Therapies in Personalised Cancer Care

Targeted therapies focus on the specific genetic and molecular changes that drive a tumour’s growth, rather than only on the part of the body where the cancer started. Molecular testing and next-generation sequencing are used to analyse the tumour’s DNA and other biomarkers, identifying alterations such as EGFR mutations in lung cancer or BRAF mutations in colorectal cancer.

These findings can guide the selection of drugs that inhibit the abnormal proteins produced by these genetic changes. Examples include trastuzumab for HER2-amplified cancers and EGFR-targeting antibodies for colorectal cancers that are KRAS wild-type.

As cancers can change over time and develop resistance, ongoing monitoring is important. This may include repeated tissue biopsies or liquid biopsies that detect circulating tumour DNA in the blood, allowing clinicians to identify emerging resistance mechanisms and adjust treatment when appropriate.

Despite the growing evidence base and availability of these tests and drugs, many patients who could benefit from targeted therapies don't receive them. Factors contributing to this include limited access to molecular testing, variability in healthcare resources, and differences in clinician awareness or local guidelines.

Immunotherapy and Personalised Cancer Vaccines

Building on targeted therapies, immunotherapy adds another layer of personalisation by engaging the immune system to recognise and attack cancer cells based on specific features. Instead of using a uniform treatment approach, clinicians can select immune checkpoint inhibitors according to the characteristics of the tumour and the patient’s immune profile, for example by targeting pathways such as PD-1/PD-L1 or CTLA-4 to help restore a more effective immune response.

Personalised cancer vaccines are another area of development. These vaccines can use mRNA or other platforms to direct the immune system toward “private” tumour mutations, meaning that two individuals with the same cancer type may receive different vaccine formulations.

Early clinical data, particularly in melanoma and some forms of lung cancer, suggest that this strategy can enhance anti-tumour immunity in certain settings, although its long-term effectiveness and optimal use are still being investigated in ongoing trials.

Liquid Biopsies for Personalised Cancer Monitoring

Liquid biopsies provide a less invasive method for monitoring cancer by analyzing small fragments of tumor DNA and other cancer-derived components circulating in the bloodstream.

By using blood samples instead of repeated tissue biopsies, clinicians can measure circulating tumor DNA (ctDNA) at multiple time points.

This allows them to assess changes in tumor burden, detect emerging resistance mutations, and evaluate response to treatment with fewer procedural risks and greater convenience for the patient.

Personalising Cancer Care Around Culture and Goals

Although precision medicine is often discussed in terms of genes and targeted therapies, personalized cancer care also involves aligning treatment with a person’s circumstances and preferences.

Factors such as culture, language, religion, financial situation, education, daily responsibilities, and personal identity all affect what types of care are feasible and acceptable.

Care teams can ask patients about their priorities such as maintaining work, caring for family, managing symptoms, or observing spiritual or cultural practices and incorporate these into treatment planning and communication.

Systematic use of patient‑reported symptoms and concerns between visits can help multidisciplinary teams identify barriers to care, including transportation challenges, rural residence, or scheduling constraints, and make appropriate adjustments.

This kind of culturally informed, goal‑aligned approach is associated with improved patient experience and may contribute to reducing disparities in cancer outcomes across different populations.

Closing Inequities in Access to Personalised Care

Even as precision oncology advances, access to personalized cancer care remains uneven and is influenced by factors such as race, income, education, and geography. Data illustrate these disparities: approximately 64% of eligible patients with advanced non-small cell lung cancer don't receive precision therapies, despite clinical guidelines and evidence of benefit. Black patients experience higher mortality rates for several cancers, and Black women have a higher likelihood of dying from breast cancer compared with White women, even after accounting for incidence differences. Regions such as rural Appalachia show higher rates of colorectal, lung, and cervical cancers, reflecting a combination of limited healthcare access, socioeconomic barriers, and structural factors.

Addressing these inequities requires coordinated policy, clinical, and system-level actions. Measures that can contribute to narrowing these gaps include universal biomarker testing consistent with evidence-based guidelines, reimbursement policies that adequately cover testing and associated services, efforts to reduce the direct and indirect costs of testing for patients, and investments in local and regional infrastructure to ensure timely, accurate molecular testing and reporting. Strengthening these components can support more equitable access to personalized cancer care and help align real-world practice with current scientific capabilities.

How AI and Tumour Boards Improve Cancer Decisions

As cancer treatment becomes more complex, artificial intelligence (AI) systems and molecular tumor boards (MTBs) are being used together to support more consistent and individualized treatment decisions. AI can systematically review large volumes of genomic, proteomic, and clinical data, helping clinicians interpret mutation profiles and identify therapies that are most likely to be relevant based on current evidence and guidelines.

In MTBs, multidisciplinary specialists examine next-generation sequencing (NGS) and biomarker results and link specific alterations such as EGFR or BRAF mutations to targeted therapies, immunotherapies, or combination approaches when appropriate. Evidence-based decision-support tools can incorporate factors such as disease stage, comorbidities, prior treatments, and predicted response, helping to structure and standardize recommendations.

AI-assisted, supervised workflows can also track test results, documentation, and referral steps, which may help reduce administrative delays and improve access to precision therapies for eligible patients.

The Future of Even More Personalised Cancer Care

Building on AI-supported tumor boards, the next phase of personalized cancer care is expected to rely less on single-gene tests and more on integrating multiple data types (genomic, transcriptomic, proteomic, and possibly metabolomic) with each patient’s clinical history. This could allow treatment decisions to be adjusted more frequently as new information about a tumor’s biology becomes available.

Liquid biopsies that measure circulating tumor DNA may enable earlier detection of molecular progression than standard imaging in some settings, potentially allowing clinicians to alter therapy before radiologic relapse is visible. However, their use will need to be guided by evidence from clinical trials to determine when changes in management based on these tests improve outcomes.

Although tools for predicting treatment response are advancing, methods for reliably forecasting toxicity remain less developed. As a result, systematic, real-time symptom reporting often through digital platforms will likely play a larger role in identifying adverse effects early and initiating pre-defined escalation or supportive care plans.

To implement these approaches at scale, health systems will need to address infrastructure requirements (such as data integration and interoperability), reimbursement models that cover complex testing and targeted therapies, and equity concerns, including access to molecular diagnostics and clinical trials. These factors will influence whether patients who are eligible for precision therapies can receive them in routine practice.

Conclusion

You’ve seen how cancer care’s shifting from “one-size-fits-all” to treatment that fits you your tumour’s genetics, your body, your culture, and your goals. As testing, liquid biopsies, and AI-supported tumour boards improve, you’ll gain more precise options and better monitoring with fewer unnecessary side effects. The key is staying informed, asking questions, and working with a team that treats you as a partner, so your care truly reflects who you are.